New Federal Contractors — March 26, 2026

Three contracts totaling $792.8M obligation (Westat $505M PATH study to 2028, PPD $126M COVID assays to 2029, Advanced $161M biotech to 2027) provide long-term cash flow with $236M outlayed.

AATD LLC's $138M obligation (potential $423M options) with 88% outlayed underscores set-aside advantages in end-user IT services through 2026.

Acacia's $832M legal services (94% outlayed) and Advanced Tech's BARDA award signal reliable flows but no equity exposure as nonprofits.

Long performance periods (2026-2029) across 80% of value expose to funding shifts and T&M caps.

COVID-19 focus in PPD ($126M) vulnerable to priority de-escalation post-pandemic.

Subawards >15% of value (Acacia $285M/34%; Westat $27M/5%) risk delays/disputes.

$694M unexercised options (Westat $455M, AATD $285M) in bullish contracts warrant monitoring for obligation increases.

HHS BARDA biotech/COVID R&D ($287M) signals follow-on potential for health contractors.

SDVOSB/8(a) set-asides in VA IT enable AATD-like wins amid $138M precedent.

$793M (45% total) in PATH, biotech, COVID immunogenicity via NIH/BARDA, with periods to 2029.

VA's $423M potential SDVOSB IT award highlights protected competition in telecom/end-user services.

DOI's $832M (47% total) T&M for unaccompanied children, 94% outlayed with heavy subawards.

{"entity"=>"Westat, Inc.", "reason"=>"$505M HHS PATH obligation with $455M options to 2028; highest bullish value.", "trigger"=>"option exercises >$100M or outlays >$300M"}

{"entity"=>"PPD DEVELOPMENT LP", "reason"=>"$126M BARDA COVID R&D to 2029; full options committed but pandemic-sensitive.", "trigger"=>"outlay acceleration or HHS COVID budget cuts"}

{"entity"=>"AATD LLC", "reason"=>"SDVOSB $423M VA IT potential; 88% current obligation outlayed.", "trigger"=>"additional VA task orders or set-aside wins"}